Molecular differences between younger versus older ER-positive and HER2-negative breast cancers

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers

The RxPONDER and TAILORx trials demonstrated benefit from adjuvant chemotherapy in patients age ≤ 50 with node-positive breast cancer and Recurrence Score (RS) 0–26, and in node-negative disease with RS 16–25, respectively, but no benefit in older women with the same clinical features. We analyzed t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NPJ breast cancer 2022-11, Vol.8 (1), p.119-119, Article 119
Hauptverfasser: Qing, Tao, Karn, Thomas, Rozenblit, Mariya, Foldi, Julia, Marczyk, Michal, Shan, Naing Lin, Blenman, Kim, Holtrich, Uwe, Kalinsky, Kevin, Meric-Bernstam, Funda, Pusztai, Lajos
Format: Artikel
Sprache:eng
Schlagworte:
631/67/69
692/53/2422
Biomedical and Life Sciences
Biomedicine
Breast cancer
Cancer
Cancer Research
Cell Biology
Chemotherapy
Gene expression
Human Genetics
Mutation
Oncology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The RxPONDER and TAILORx trials demonstrated benefit from adjuvant chemotherapy in patients age ≤ 50 with node-positive breast cancer and Recurrence Score (RS) 0–26, and in node-negative disease with RS 16–25, respectively, but no benefit in older women with the same clinical features. We analyzed transcriptomic and genomic data of ER+/HER2− breast cancers with in silico RS 
ISSN:2374-4677
2374-4677
DOI:10.1038/s41523-022-00492-0